O	0	6	Effect
O	7	9	of
B-intervention	10	19	tamoxifen
O	20	22	on
B-condition	23	29	venous
I-condition	30	44	thromboembolic
I-condition	45	51	events
O	52	54	in
O	55	56	a
O	57	63	breast
O	64	70	cancer
O	71	81	prevention
O	82	87	trial
O	87	88	.

O	89	98	Tamoxifen
O	98	99	,
O	100	101	a
O	102	111	selective
O	112	120	estrogen
O	120	121	-
O	121	129	receptor
O	130	139	modulator
O	139	140	,
O	141	150	increases
O	151	157	venous
O	158	172	thromboembolic
O	173	179	events
O	180	181	(
O	181	184	VTE
O	184	185	)
O	185	186	,
O	187	190	but
O	191	194	the
O	195	202	factors
O	203	213	explaining
O	214	218	this
O	219	223	risk
O	224	227	are
O	228	235	unclear
O	235	236	.

O	237	252	Atherosclerosis
O	253	256	may
O	257	263	induce
O	264	267	VTE
O	267	268	,
O	269	271	or
O	272	275	the
O	276	277	2
O	278	288	conditions
O	289	292	may
O	293	298	share
O	299	305	common
O	306	310	risk
O	311	318	factors
O	318	319	.

O	320	322	We
O	323	331	assessed
O	332	335	the
O	336	342	effect
O	343	345	of
O	346	355	tamoxifen
O	356	358	on
O	359	362	VTE
O	363	365	in
O	366	367	a
O	368	374	breast
O	375	381	cancer
O	382	392	prevention
O	393	398	trial
O	399	402	and
O	403	410	studied
O	411	414	its
O	415	426	association
O	427	431	with
O	432	436	risk
O	437	444	factors
O	445	448	for
O	449	452	VTE
O	452	453	.

O	454	457	The
O	458	467	incidence
O	468	470	of
O	471	474	VTE
O	475	478	was
O	479	486	studied
O	487	489	in
B-total-participants	490	494	5408
B-eligibility	495	510	hysterectomized
I-eligibility	511	516	women
O	517	525	randomly
O	526	534	assigned
O	535	537	to
O	538	547	tamoxifen
O	548	550	20
O	551	553	mg
O	553	554	/
O	554	555	d
O	556	558	or
B-control	559	566	placebo
O	567	570	for
O	571	572	5
O	573	578	years
O	578	579	.

O	580	585	There
O	586	590	were
B-cv-bin-abs	591	593	28
B-outcome	594	598	VTEs
O	599	601	on
O	602	609	placebo
O	610	613	and
B-iv-bin-abs	614	616	44
O	617	619	on
O	620	629	tamoxifen
O	630	637	therapy
O	638	639	(
O	639	645	hazard
O	646	651	ratio
O	652	653	[
O	653	655	HR
O	655	656	]
O	656	657	=
O	657	658	1
O	658	659	.
O	659	661	63
O	661	662	;
O	663	665	95
O	665	666	%
O	667	677	confidence
O	678	686	interval
O	687	688	[
O	688	690	CI
O	690	691	]
O	691	692	,
O	693	694	1
O	694	695	.
O	695	697	02
O	698	700	to
O	701	702	2
O	702	703	.
O	703	705	63
O	705	706	)
O	706	707	,
O	708	710	80
O	710	711	%
O	712	714	of
O	715	720	which
O	721	725	were
O	726	737	superficial
O	738	747	phlebitis
O	747	748	,
O	749	759	accounting
O	760	763	for
O	764	767	all
O	768	770	of
O	771	774	the
O	775	781	excess
O	782	785	due
O	786	788	to
O	789	798	tamoxifen
O	799	805	within
O	806	808	18
O	809	815	months
O	816	820	from
O	821	834	randomization
O	834	835	.

O	836	844	Compared
O	845	849	with
O	850	857	placebo
O	857	858	,
O	859	862	the
B-outcome	863	867	risk
I-outcome	868	870	of
I-outcome	871	874	VTE
O	875	877	on
O	878	887	tamoxifen
O	888	891	was
O	892	898	higher
O	899	901	in
O	902	907	women
O	908	912	aged
O	913	915	55
O	916	921	years
O	922	924	or
O	925	930	older
O	930	931	,
O	932	937	women
O	938	942	with
O	943	944	a
O	945	949	body
O	950	954	mass
O	955	960	index
O	961	962	>
O	963	965	or
O	966	967	=
O	967	969	25
O	970	972	kg
O	972	973	/
O	973	975	m2
O	975	976	,
O	977	985	elevated
O	986	991	blood
O	992	1000	pressure
O	1000	1001	,
O	1002	1007	total
O	1008	1019	cholesterol
O	1020	1021	>
O	1022	1024	or
O	1025	1026	=
O	1026	1029	250
O	1030	1032	mg
O	1032	1033	/
O	1033	1035	dL
O	1035	1036	,
O	1037	1044	current
O	1045	1052	smoking
O	1052	1053	,
O	1054	1057	and
O	1058	1059	a
O	1060	1066	family
O	1067	1074	history
O	1075	1077	of
O	1078	1086	coronary
O	1087	1092	heart
O	1093	1100	disease
O	1101	1102	(
O	1102	1105	CHD
O	1105	1106	)
O	1106	1107	.

O	1108	1110	Of
O	1111	1114	the
O	1115	1118	685
O	1119	1124	women
O	1125	1129	with
O	1130	1131	a
O	1132	1135	CHD
O	1136	1140	risk
O	1141	1146	score
O	1147	1148	>
O	1149	1151	or
O	1152	1153	=
O	1153	1154	5
O	1155	1158	who
O	1159	1166	entered
O	1167	1170	the
O	1171	1176	trial
O	1176	1177	,
B-cv-bin-abs	1178	1179	1
O	1180	1182	in
O	1183	1186	the
O	1187	1194	placebo
O	1195	1198	arm
O	1199	1202	and
B-iv-bin-abs	1203	1205	13
O	1206	1208	in
O	1209	1212	the
O	1213	1222	tamoxifen
O	1223	1226	arm
B-outcome	1227	1236	developed
I-outcome	1237	1240	VTE
O	1241	1242	(
O	1242	1245	log
O	1245	1246	-
O	1246	1250	rank
O	1251	1252	P
O	1252	1253	=
O	1253	1254	0
O	1254	1255	.
O	1255	1259	0013
O	1259	1260	)
O	1260	1261	.

O	1262	1264	In
O	1265	1277	multivariate
O	1278	1288	regression
O	1289	1297	analysis
O	1297	1298	,
O	1299	1302	age
O	1303	1304	>
O	1305	1307	or
O	1308	1309	=
O	1309	1311	60
O	1312	1317	years
O	1317	1318	,
O	1319	1325	height
O	1326	1327	>
O	1328	1330	or
O	1331	1332	=
O	1332	1335	165
O	1336	1338	cm
O	1338	1339	,
O	1340	1343	and
O	1344	1353	diastolic
O	1354	1359	blood
O	1360	1368	pressure
O	1369	1370	>
O	1371	1373	or
O	1374	1375	=
O	1375	1377	90
O	1378	1380	mm
O	1381	1383	Hg
O	1384	1387	had
O	1388	1399	independent
O	1400	1411	detrimental
O	1412	1419	effects
O	1420	1422	on
O	1423	1426	VTE
O	1427	1431	risk
O	1432	1438	during
O	1439	1448	tamoxifen
O	1449	1456	therapy
O	1456	1457	,
O	1458	1465	whereas
O	1466	1477	transdermal
O	1478	1486	estrogen
O	1487	1494	therapy
O	1495	1506	concomitant
O	1507	1511	with
O	1512	1521	tamoxifen
O	1522	1525	was
O	1526	1529	not
O	1530	1540	associated
O	1541	1545	with
O	1546	1549	any
O	1550	1556	excess
O	1557	1559	of
O	1560	1563	VTE
O	1564	1565	(
O	1565	1567	HR
O	1567	1568	=
O	1568	1569	0
O	1569	1570	.
O	1570	1572	64
O	1572	1573	;
O	1574	1576	95
O	1576	1577	%
O	1578	1580	CI
O	1580	1581	,
O	1582	1583	0
O	1583	1584	.
O	1584	1586	23
O	1587	1589	to
O	1590	1591	1
O	1591	1592	.
O	1592	1594	82
O	1594	1595	)
O	1595	1596	.

O	1597	1602	Women
O	1603	1607	with
O	1608	1620	conventional
O	1621	1625	risk
O	1626	1633	factors
O	1634	1637	for
O	1638	1653	atherosclerosis
O	1654	1658	have
O	1659	1660	a
O	1661	1667	higher
O	1668	1672	risk
O	1673	1675	of
O	1676	1679	VTE
O	1680	1686	during
O	1687	1696	tamoxifen
O	1697	1704	therapy
O	1704	1705	.

O	1706	1710	This
O	1711	1722	information
O	1723	1729	should
O	1730	1732	be
O	1733	1745	incorporated
O	1746	1750	into
O	1751	1761	counseling
O	1762	1767	women
O	1768	1770	on
O	1771	1774	its
O	1775	1779	risk
O	1779	1780	-
O	1780	1787	benefit
O	1788	1793	ratio
O	1793	1794	,
O	1795	1807	particularly
O	1808	1810	in
O	1811	1814	the
O	1815	1825	prevention
O	1826	1833	setting
O	1833	1834	.
